Insulet to Share Omnipod Clinical Data at Three Major European National Diabetes Congresses

• Diabetes UK Professional Conference (Diabetes UK), March 14-16 at ExCeL, London
• Société Francophone du Diabète (SFD) Annual Conference, March 20-23 at Cité des Congrès de Nantes, France
• Deutsche Diabetes Gesellschaft (DDG) Diabetes Kongress, May 9-12 at CityCube Berlin, Germany

Insulet will have a booth presence at each meeting to allow its fast-growing European team to interact directly with the diabetes community. Additionally, at Diabetes UK, Insulet will hold a sponsored symposium, “The Omnipod Insulin Management System: Real-world use and future innovation” on Thursday, March 15, in Room 1 from 6:35–7:35 p.m. (local time). Healthcare professionals attending these congresses will also have the opportunity take the “Pod Challenge” to experience first-hand the simplicity and ease of use that the Omnipod System offers users globally.

The Company’s presence at these major European meetings will provide a platform for the local Insulet teams to more broadly communicate the Company’s plans to transition to direct operations in Europe to distribute and support its Omnipod System on July 1, 2018. The latest news about the transition in Europe is available at https://www.omnipodeurope.com.

“We are excited to attend these important national congresses and support the diabetes communities in Europe,” said Patrick Sullivan, Chairman and Chief Executive Officer. “We are confident our local teams have the experience and talent necessary to transition this business successfully and to drive increased value for our customers and all of our stakeholders.”

About the Omnipod Insulin Management System:

The Omnipod Insulin Management System is an innovative continuous insulin delivery system that provides all the proven benefits of continuous subcutaneous insulin infusion (CSII) therapy in a way no conventional insulin pump can. The Omnipod System's innovative design and features allows people living with diabetes to live their life—and manage their diabetes—with unprecedented freedom, comfort, convenience, and ease. The Omnipod System consists of two components: (i) a Pod that stores and delivers insulin; and (ii) a Personal Diabetes Manager (PDM) that wirelessly programs the user's personalized insulin delivery, calculates suggested doses and insulin on board, and has a convenient, built-in blood glucose meter. The small, light-weight Pod can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh or lower back and, because it is waterproof (IPX8), there is no need to remove when showering, swimming or performing other activities. This means that Omnipod can provide up to three days of non-stop insulin delivery, without the need to disconnect a tube set or manually inject insulin. The Pod and PDM communicate wirelessly to offer precise, personalized and continuous insulin delivery with customizable basal and bolus delivery options, as well as important safety checks. The Pod's auto-cannula insertion is quick, simple, and virtually pain-free. Users never have to handle a needle. The user simply pushes a button on the PDM and the Pod's automated insertion system inserts the cannula beneath the skin and begins delivering insulin according to the user's programmed basal rate.

The Omnipod System is the world's first commercially available tubeless insulin delivery system that allows users to live untethered by tubing and without the stress and anxiety of multiple daily injections. By breaking down the barriers to insulin pump therapy, the Omnipod System offers freedom for users to live life on their own terms and with the ease of use they deserve.